Pluvia is a biotechnology company that was established in 2015, as a spin-out from The University of Bergen, Norway. Pluvia is developing effective drugs to treat genetic disorders that are associated with protein misfolding. Pluvia core activities are based on the therapeutic concept of pharmacological chaperones, small molecules that prevent the instability and misfolding by selectively binding to key sites of the mutant proteins.

Our lead development program is focusing on phenylketonuria (PKU), a rare genetic disorder caused by mutations in the enzyme phenylalanine hydroxylase that result in defective degradation and accumulation of the amino acid phenylalanine, which becomes toxic to the brain.

The company intends to develop a proprietary technology platform and leverage our unique drug discovery platform to target multiple rare disease caused by protein misfolding.